RT Journal Article
SR Electronic
A1 Lederman, Lynne
T1 Eluxadoline Shows Efficacy for IBS-D in IBS3001 and IBS3002 Phase 3 Trials
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 14
SP 12
OP 13
DO 10.1177/1559897715593926
UL http://mdc.sagepub.com/content/15/14/12.2.abstract
AB Eluxadoline, a µ-opioid receptor agonist and d-opioid receptor antagonist, exhibits rapid onset of action along with sustained efficacy over the 6-month treatment period as studied in the phase 3, double-blind, placebo-controlled IBS3001 and IBS3002 trials in patients with diarrhea-predominant irritable bowel syndrome.